Ascletis Pharma Inc.

HK$4.55As of Sun 8 Nov 2026, 12:00 UTC
HKEX:1672Healthcare
Country Hong Kong
PE (Fwd) •••
TSR 8Y CAGR (8.29%)
Div yield —
ROE (28.59%)
Biotechnology
Beta (5Y) 0.53
PE TTM —
TSR TTM (52.85%)
Mkt cap HK$4.806B
ROIC (21.07%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$5.42
19.03%
(60.51%)
Hold 8|2|11|8|8
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.08
0.08
0.08
0.08
16.38%
24.72%
13.90%
9.46%
Revenue¥M
603.9
612.5
596.2
589.6
12.22%
10.79%
3.77%
3.41%
Peers (US$613.1M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
3.022
0.311
0.311
EBIT/Intx
0.463
0.099
0.112
Own earn%
(31.09)
(63.60)
(51.59)
Sh yield%
48.57
30.29
30.79
Owners
Insiders/Inst%
3.87
47.90
Short interest%
1.37
SBC / revenue%
2.39
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
18
Op margin range%
14–20
$1 testx
−1.8
Incr. ROIC%
1